GSK3B and triple-negative breast carcinoma: MiR-27a enhances the proliferation of triple-negative breast cancer (TNBC) cells by targeting glycogen synthase kinase-3 beta (GSK-3β), leading to the release of β-catenin and its translocation into the nucleus.